百洋醫藥(301015.SZ):子公司與羅氏製藥簽訂《推廣協議》
格隆匯2月13日丨百洋醫藥(301015.SZ)公佈,公司全資子公司北京百洋智合醫學成果轉化服務有限公司(簡稱“百洋智合”)與上海羅氏製藥有限公司(簡稱“羅氏製藥”)簽訂了《推廣協議》,約定羅氏製藥聘請百洋智合在區域(中華人民共和國,不包括台灣、香港和澳門地區)內獨家推廣產品(利妥昔單抗注射液,商品名:美羅華®)。羅氏將根據協議約定每季度向百洋支付一筆推廣服務費。百洋將向羅氏開具增值税專用發票,羅氏將在確認正確的發票後六十(60)日內付款。推廣服務費=基本服務費+業績服務費。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.